Skip to main content
. Author manuscript; available in PMC: 2017 Apr 28.
Published in final edited form as: Circulation. 2013 Dec 18;129(3):e28–e292. doi: 10.1161/01.cir.0000441139.02102.80

Table 22-7.

National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care, 2011

Commercial Medicare Medicaid
AMI
 β-Blocker persistence* 81.3 87.3 80.5
Cholesterol management for patients with CVD
 Cholesterol screening 88.1 88.8 82.0
 LDL cholesterol control (<100 mg/dL) 59.8 56.5 42.1
Hypertension
 BP <140/90 mm Hg 65.4 64.0 56.8
DM
 HbA1c testing 90.0 91 82.5
 HbA1c >9.0% 28.3 26.5 43.0
 Eye examination performed 56.9 66.0 53.3
 LDL cholesterol screening 85.3 88.3 75.0
 LDL cholesterol <100 mg/dL 48.1 52.5 35.2
 Monitoring nephropathy 83.8 89.9 77.8
 BP <140/90 mm Hg 65.8 63.1 60.9
Advising smokers and tobacco users to quit 77.6 81.5 74.6
BMI percentile assessment in children and adolescents 44.7 N/A 46
Nutrition counseling (children and adolescents) 46.4 N/A 50.1
Counseling for physical activity (children and adolescents) 43.0 N/A 40.6
BMI assessment for adults 55.4 68.2 52.6
Physical activity discussion in older adults (≥65 y of age) N/A 53.0 N/A
Physical activity advice in older adults (≥65 y of age) N/A 48.7 N/A

Values are percentages.

AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DM, diabetes mellitus; HbA1c, hemoglobin A1c; LDL, low-density lipoprotein; and N/A, not available or not applicable.

*

β-Blocker persistence: Received persistent β-blocker treatment for 6 mo after AMI hospital discharge.